Our mission: transforming the patient’s experience with our passion, know-how and dedication..
Partner Stories
AOP Health and RHEACELL
AOP Health and RHEACELL have formed a strategic partnership to deliver breakthrough therapies for the "butterfly children's" disease Epidermolysis bullosa (EB) and chronic venous ulcers. This partnership aims to provide patients with high unmet medical needs access to innovative cell therapies.
Read more here: RHEACELL and AOP Health: Strategic Partnership
Dr. Martin Steinhart
Our mission is to provide patients with rare diseases access to urgently needed therapeutic innovation. This partnership with stem cell pioneer RHEACELL enables us to jointly bring new treatment options to patients living with chronic venous wounds or Epidermolysis bullosa, who currently have limited or no treatment options. Our teams are fully committed to making these groundbreaking treatments available to all patients affected.
Dr. Christoph Ganss
This partnership marks a significant milestone for RHEACELL and the further development of our stem cell medication programs. Collaborating with an established partner like AOP Health to commercialize our stromal cell medications will allow us to bring our innovative therapies to the European patients faster and more efficiently.
Dr. Rainer Riedl
RHEACELL's approach of administering stromal cells systemically to stimulate internal and external wound healing distinguishes it from other approaches that focus primarily on local applications on the skin. We are thrilled to follow the ongoing clinical development.
Univ.-Prof. Dr. Johann Bauer
In treating Epidermolysis bullosa, we have had few therapeutic options to date. This lack of treatment options adds an additional burden on those affected. From a medical perspective, the concept of regenerative, anti-inflammatory cell therapy is a promising approach. That’s why our study center is participating in the next milestone—Phase 3 trials.
Andreas di Egidio
This alliance came together because of shared values, trust, and a deep belief in what science can achieve. By joining forces with RHEACELL, we are strengthening our innovation pipeline and giving AOP Health an additional growth engine—one that supports our expansion into new therapeutic areas and markets.
Eszter Kormann
From the earliest stages of asset evaluation through to contracting, the professional chemistry between the AOP Health and RHEACELL teams was evident. With a shared mindset and mutual commitment, we’ve built a strong foundation — and we’re truly looking forward to shaping the future together.
Dr. Michael Caballero
Being one of our preferred partners since the day OrPha Swiss GmbH was founded, our collaboration with AOP Health has played a crucial role in the success and build-up of our small Swiss niche pharma company. Now, after 14 years of collaboration, AOP Health has proven to be not only a reliable and professional business partner but also an innovator and problem-solver in the pharmaceutical niche and in the orphan drug sector.
Jonathan Hahn
Our collaboration with AOP Health will allow many neglected patients suffering from pulmonary arterial hypertension to gain access to medical treatment. We hope that our continued joint efforts will allow both of our companies to expand even further in the Latin American market in the coming years.
Alejandro Snitowski
We have been partnering with AOP Health for almost a decade, helping thousands of patients with Huntington`s Disease to improve their quality of life in Chile, Peru, Colombia, Venezuela, and Mexico. During all these years, we have always found a way to build our partnership with open communication and a professional approach to solving regulatory issues.
Dr. Harald Jainta
For decades, we have been a partner of AOP Health in distribution arrangements, crossing products from AOP Health for Germany and brands from Desitin for Austria. AOP Health is a proven partner that works tirelessly to get transactions completed. Moreover, recent innovations of AOP Health have transformed us from a niche player into a smart development entity.